Aller au contenu principal
Profil bibliographique

Ashley M. Zeman

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

4Publications signalées
107Citations signalées
3Affiliations récentes

Les institutions déclarées

Les domaines associés

Cancer Immunotherapy and BiomarkersConnective tissue disorders researchPsoriasis: Treatment and PathogenesisColorectal Cancer Treatments and StudiesMast cells and histamine

Les publications récentes

Accès ouvert 2026 preprint OpenAlex

Mast cell score associates with wide-spread mast cell symptoms and comorbidities in patients with hEDS and HSD

Frances C. Wilson, Derek J. Zangerle, Lincoln E. Rozen, Jessica J. Fliess et autres

Abstract Background Wide-spread mast cell (MC)-associated symptoms and MC activation syndrome (MCAS) are often reported in patients with hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD). The goal of this study was to develop a novel MC score based on 11 …

us (code pays fourni par la source)

0 citations medRxiv
Accès ouvert 2023 article OpenAlex

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Faisal Fa’ak, Maryam Buni, Adewunmi Falohun, Huifang Lu et autres

BACKGROUND: Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness of anti-interleukin-6 receptor (anti-IL-6R) as therapy for irAEs. …

us, Égypte (code pays fourni par la source)

104 citations Journal for ImmunoTherapy of Cancer
Accès ouvert 2021 conference-abstract OpenAlex

816 Selective immune suppression using interleukin-6 blockade in immune related adverse events

Faisal Fa’ak, Chrystia M. Zobniw, Maryam Buni, L Lu et autres

Background Managing immune-related adverse events (irAEs) has become a critical challenge with the increasing implementation of immune-checkpoint inhibitors (ICIs) in cancer treatment. IrAEs may cause treatment interruption or discontinuation, the rate of which is higher with multi-agent ICI regimen needed to overcome …

us (code pays fourni par la source)

1 citation Regular and Young Investigator Award Abstracts

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.